Dr. John H. Noseworthy Nominated to Stand for Election to Merck Board of Directors
April 10 2017 - 3:30PM
Business Wire
Merck (NYSE: MRK), known as MSD outside the United States and
Canada, today announced that Dr. John H. Noseworthy, president and
chief executive officer of Mayo Clinic, has been nominated to stand
for election to the company’s board of directors. The annual
election of Dr. Noseworthy and the other directors will take place
in connection with Merck’s Annual Meeting of Shareholders on May
23, 2017. With the proposed addition of Dr. Noseworthy, and the
planned retirement of C. Robert Kidder, the Merck board will
include 13 members.
“We are pleased to nominate Dr. John Noseworthy to stand for
election to the Merck board and look forward to benefiting from his
first-hand insights about patient care and health care delivery as
a leader of one of the largest non-profit health systems in the
United States,” said Kenneth C. Frazier, chairman and chief
executive officer, Merck.
Dr. John H. Noseworthy is president and chief executive officer
of Mayo Clinic, a not-for-profit organization operating in five
states that is dedicated to medical care, research and education.
Prior to his current appointment, he served as chair of Mayo
Clinic’s Department of Neurology, medical director of the
Department of Development, and vice chair of the Mayo Clinic
Rochester Executive Board. Dr. Noseworthy is a professor in the
Department of Neurology and served as editor-in-chief for
Neurology, the official journal of the American Academy of
Neurology.
Dr. Noseworthy earned his medical degree from Dalhousie
University in Halifax, Nova Scotia, Canada. He completed his
neurology training at Dalhousie University and the University of
Western Ontario, and a research fellowship at Harvard Medical
School. He has received the Alumnus of the Year award from
Dalhousie University, an honorary doctorate of science degree from
the University of Western Ontario, and an honorary doctorate of
laws from Dalhousie University. He also is a Health Governor of the
World Economic Forum.
About Merck
For over a century, Merck has been a global health care leader
working to help the world be well. Merck is known as MSD outside
the United States and Canada. Through our prescription medicines,
vaccines, biologic therapies, and animal health products, we work
with customers and operate in more than 140 countries to deliver
innovative health solutions. We also demonstrate our commitment to
increasing access to health care through far-reaching policies,
programs and partnerships. For more information, visit
www.merck.com and connect with us on Twitter, Facebook, YouTube and
LinkedIn.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J.,
USA (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of pharmaceutical industry regulation and health care
legislation in the United States and internationally; global trends
toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory
approval; the company’s ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of the company’s patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2016
Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170410006137/en/
MerckMedia:Tracy Ogden, 215-370-5597orInvestors:Teri Loxam,
908-740-1986
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2024 to May 2024
Merck (NYSE:MRK)
Historical Stock Chart
From May 2023 to May 2024